JP5274831B2 - リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用 - Google Patents

リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用 Download PDF

Info

Publication number
JP5274831B2
JP5274831B2 JP2007505094A JP2007505094A JP5274831B2 JP 5274831 B2 JP5274831 B2 JP 5274831B2 JP 2007505094 A JP2007505094 A JP 2007505094A JP 2007505094 A JP2007505094 A JP 2007505094A JP 5274831 B2 JP5274831 B2 JP 5274831B2
Authority
JP
Japan
Prior art keywords
ryr2
jtv
cardiac
alkyl
ventricular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007505094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530561A (ja
JP2007530561A5 (enExample
Inventor
アンドリュー アール マークス
ドナルド ダブリュー ランドリー
シーシァン デン
ゼン ズアン チェン
Original Assignee
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク filed Critical ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク
Publication of JP2007530561A publication Critical patent/JP2007530561A/ja
Publication of JP2007530561A5 publication Critical patent/JP2007530561A5/ja
Application granted granted Critical
Publication of JP5274831B2 publication Critical patent/JP5274831B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007505094A 2004-03-25 2005-03-22 リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用 Expired - Fee Related JP5274831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/809,089 2004-03-25
US10/809,089 US7718644B2 (en) 2004-01-22 2004-03-25 Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
PCT/US2005/009495 WO2005094457A2 (en) 2004-03-25 2005-03-22 Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012208868A Division JP2012250999A (ja) 2004-03-25 2012-09-21 リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用

Publications (3)

Publication Number Publication Date
JP2007530561A JP2007530561A (ja) 2007-11-01
JP2007530561A5 JP2007530561A5 (enExample) 2008-05-08
JP5274831B2 true JP5274831B2 (ja) 2013-08-28

Family

ID=34990842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007505094A Expired - Fee Related JP5274831B2 (ja) 2004-03-25 2005-03-22 リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用
JP2012208868A Abandoned JP2012250999A (ja) 2004-03-25 2012-09-21 リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012208868A Abandoned JP2012250999A (ja) 2004-03-25 2012-09-21 リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用

Country Status (25)

Country Link
US (1) US7718644B2 (enExample)
EP (3) EP2127654B1 (enExample)
JP (2) JP5274831B2 (enExample)
KR (2) KR20070041432A (enExample)
CN (2) CN101704799B (enExample)
AU (1) AU2005227907B2 (enExample)
BR (1) BRPI0509199A (enExample)
CA (1) CA2560866A1 (enExample)
CY (1) CY1113426T1 (enExample)
DK (1) DK2163248T3 (enExample)
EA (1) EA015010B1 (enExample)
ES (1) ES2394104T3 (enExample)
GE (1) GEP20115301B (enExample)
HR (1) HRP20120938T1 (enExample)
IL (1) IL178157A (enExample)
MA (1) MA28629B1 (enExample)
NO (1) NO20064843L (enExample)
NZ (1) NZ550750A (enExample)
PL (1) PL2163248T3 (enExample)
PT (1) PT2163248E (enExample)
RS (1) RS52601B (enExample)
SG (1) SG153862A1 (enExample)
SI (1) SI2163248T1 (enExample)
UA (1) UA96914C2 (enExample)
WO (1) WO2005094457A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007069453A1 (ja) * 2005-12-14 2007-06-21 Eisai R & D Management Co., Ltd. 心電図ｑｔ時間延長作用の評価法
WO2007127145A2 (en) * 2006-04-25 2007-11-08 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of cardiac arrhythmia in non-human animals
US20110263569A1 (en) * 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
EA028108B1 (ru) 2008-03-03 2017-10-31 Армго Фарма, Инк. Способ получения бензотиазепинов из гамма-аминоалкилбензолов
US8642586B2 (en) * 2009-02-25 2014-02-04 Noboru Kaneko 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same
WO2010114562A1 (en) * 2009-04-03 2010-10-07 Sequel Pharmaceuticals, Inc. Improved methods of administration of k201 (jtv-519) (4-[3-{1-(4-benzyl) piperidinyl}propionyl]-7-methoxy 2, 3, 4, 5-tetrahydro-1, 4-benzothiazepine monohydrochloride)
EP2418950A4 (en) * 2009-04-15 2012-10-24 State Of Oregon By & Through The State Board Of Higher Education On Behalf Of Portland State Unv COMPOUNDS AND METHODS FOR MODULATING THE ACTIVITY OF CALCIUM RELEASE CHANNELS
WO2012019076A1 (en) * 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
WO2017053506A1 (en) * 2015-09-22 2017-03-30 The Johns Hopkins University P75ntr antagonists and treatment of acute and chronic cardiac disease
WO2018165171A1 (en) 2017-03-06 2018-09-13 Washington University Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
CN109010799B (zh) * 2018-07-09 2021-07-06 沣潮医药科技（上海）有限公司 RyR2蛋白或RyR2重组蛋白在制备抗心力衰竭药物中的用途
US11717526B2 (en) * 2021-05-20 2023-08-08 Armgo Pharma, Inc. Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
CN115631871B (zh) * 2022-12-22 2023-03-24 北京大学第三医院（北京大学第三临床医学院） 一种药物相互作用等级的确定方法和装置

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
US3519647A (en) 1966-10-12 1970-07-07 Squibb & Sons Inc 2,3,4,5-tetrahydro-1,5-benzothiazepines
DE3561317D1 (en) * 1984-01-27 1988-02-11 Ajinomoto Kk Manufacture of heptanoic acid derivatives
EP0238700B1 (en) 1986-03-27 1991-01-23 Topy Industries, Limited Carbon monoxide oxidizing catalyst
US4567254A (en) * 1984-09-19 1986-01-28 Kikkoman Corporation Method for preparing N6,8-disubstituted 3',5'-cyclic adenosine monophosphate and salt thereof
JPS6260A (ja) 1985-02-26 1987-01-06 Ajinomoto Co Inc シクロペンテニルヘプタン酸誘導体の製造方法
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JPS63227599A (ja) 1987-03-14 1988-09-21 Kirin Brewery Co Ltd アンスラサイクリン化合物およびその用途
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
US5179125A (en) * 1987-12-03 1993-01-12 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
DE3837575A1 (de) 1988-11-05 1990-05-10 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen
JPH0662567B2 (ja) 1988-12-27 1994-08-17 麒麟麦酒株式会社 ピリジンカルボキシイミダミド誘導体、その製造中間体、製造法および用途
US5272164A (en) 1988-12-27 1993-12-21 Kirin Beer Kabushiki Kaisha Carboximidamide derivatives
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
US5142647A (en) 1989-04-18 1992-08-25 Japan Tobacco, Inc. Magnus measuring apparatus
EP0446374B1 (en) * 1989-09-30 1996-02-07 Kirin Beer Kabushiki Kaisha Method of producing seedling
US5153184A (en) 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5075293A (en) 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US4963671A (en) 1989-11-20 1990-10-16 E. R. Squibb & Sons, Inc. Process for resolving chiral intermediates used in making calcium channel blockers
US5214056A (en) * 1989-12-27 1993-05-25 Japan Tobacco Inc. 1,3,2-dioxathiolane oxide derivative
KR920701200A (ko) * 1990-03-30 1992-08-11 미즈노 시게루 신규의 4h-3,1-벤조옥사진-4-온 유도체
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
US5082847A (en) 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
US5064810A (en) 1990-09-14 1991-11-12 Jeffrey Askanazi Use of branched chain amino acids to effect diaphragm contractility and fatigue
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2084997A1 (en) 1991-04-10 1992-10-11 Koji Kobayashi Oxazinone derivative
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
CA2090677C (en) 1991-07-04 1996-08-27 Yoshihiro Watanabe Method for culturing t lineage precursor cells
EP0638560A4 (en) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1993013082A1 (en) * 1991-12-20 1993-07-08 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
WO1994001409A1 (fr) 1992-07-02 1994-01-20 Fujisawa Pharmaceutical Co., Ltd. Nouvel intermediaire pour la synthese et la production d'un derive d'aminoacide
WO1994004523A1 (fr) * 1992-08-21 1994-03-03 Japan Tobacco Inc. Compose dioxacycloalcane a activite inhibitrice de la renine
US5260286A (en) 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
CZ288595B6 (cs) * 1992-11-09 2001-07-11 The Boots Company Plc Farmaceutické prostředky obsahující deriváty 2,3,4,5-tetrahydro-1,4-benzothiazepinů, tyto deriváty a způsob jejich výroby
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
US5780441A (en) 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5824862A (en) 1993-08-19 1998-10-20 Japan Tobacco Inc. DNA encoding ATP-dependent fructose 6-phosphate 1-phosphotransferase originating from plant, recombinant vector containing the same and method for changing sugar content in plant cells under low temperature
FR2709753B1 (fr) 1993-09-09 1995-12-01 Hoechst Lab Nitrates organiques, leur procédé de préparation et leur application comme médicaments.
CA2153498A1 (en) * 1993-11-10 1995-05-18 Hidetsura Cho Chroman derivative and medicinal use thereof
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5449675A (en) 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
WO1995034642A1 (en) * 1994-06-15 1995-12-21 Kirin Beer Kabushiki Kaisha Novel transferase and amylase, process for producing the enzymes,use thereof, and gene coding for the same
US20040175814A1 (en) 1994-06-15 2004-09-09 Kirin Beer Kubushiki Kaisha Novel transferase and amylase, process for producing the enzymes, use thereof, and gene coding for the same
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
DE69527505D1 (de) 1994-11-11 2002-08-29 Noboru Kaneko Monoklonaler antikörper gegen antiannexin-v, verfahren zu seiner herstellung und seiner verwendung
CA2205173A1 (en) 1994-11-18 1996-05-30 Takeshi Nakamura Therapeutic agent for osteoporosis and triazepine compound
DE4445548A1 (de) 1994-12-20 1996-06-27 Bayer Ag Verfahren zur Herstellung von 3-Fluor-4,6-dichlortoluol
WO1997003986A1 (en) * 1995-07-19 1997-02-06 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US6660837B1 (en) 1995-09-14 2003-12-09 Kirin Beer Kabushiki Kaisha Modified protein derived from protein kinase N
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6362231B1 (en) 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
US6111072A (en) 1996-08-26 2000-08-29 Kirin Beer Kabushiki Kaisha Rho target protein human mDia and gene encoding same
WO1998026053A1 (fr) * 1996-12-12 1998-06-18 Kirin Beer Kabushiki Kaisha NOUVELLE β1→4 N-ACETYLGLUCOSAMINYLTRANSFERASE ET GENE LA CODANT
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6011036A (en) 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
DE19722317C1 (de) 1997-05-28 1998-10-08 Boehringer Ingelheim Int Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle
AUPO941497A0 (en) 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
JP4431798B2 (ja) 1997-10-08 2010-03-17 昇 金子 尿中のアネキシンｖの分析方法及びその利用
GB9724813D0 (en) 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
CA2325638A1 (en) * 1998-03-26 1999-09-30 Hideki Yamada Amide derivatives and nociceptin antagonists
DE69919149D1 (de) * 1998-04-10 2004-09-09 Japan Tobacco Inc Amidin-verbindungen
AU4550699A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
AU4930299A (en) * 1998-07-31 2000-02-21 Kirin Beer Kabushiki Kaisha Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives
WO2000016806A1 (en) 1998-09-17 2000-03-30 Nippon Kayaku Kabushiki Kaisha Remedies for photochemotherapy
DE69929362T2 (de) 1998-12-28 2006-09-28 Kaneko, Noboru verwendung von 1,4-benzothiazepinen zur Herstellung eines Medikaments ZUR BEHANDLUNG DER VORHOF-FIBRILLATION
CA2368734C (en) * 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
WO2000071132A1 (en) 1999-05-19 2000-11-30 Japan Tobacco Inc Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
DE60034494T2 (de) * 1999-09-30 2008-01-03 Noboru Kaneko Verwendung von Diphenylmethylpiperazin-Derivaten zur Herstellung eines Medikaments zur Unterdrückung der Proliferation von Fibroblasten
EP1243582A4 (en) 1999-12-24 2003-06-04 Kirin Brewery CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
EP1244457B1 (en) * 1999-12-29 2004-10-27 Glaxo Group Limited Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases
DE60109571D1 (de) 2000-01-14 2005-04-28 Migenix Corp Screening-assays unter verwendung von intramitochondrialem kalzium
NZ519981A (en) * 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
WO2001060819A1 (en) 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US6403830B2 (en) 2000-03-24 2002-06-11 Pharmacia Corporation Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001261434A1 (en) 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
CN101498731A (zh) 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
AU2001267879A1 (en) 2000-07-05 2002-01-14 Ajinomoto Co., Inc. Acylsulfonamide derivatives
EP1300142A4 (en) 2000-07-05 2004-05-19 Ajinomoto Kk HYPOGLYCEMIC COMPOUNDS
CA2415826A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
AU2001281083A1 (en) 2000-08-01 2002-02-13 Pharmacia Corporation Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase
MY131964A (en) * 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031608A1 (es) 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
US6936426B2 (en) * 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
CA2437021A1 (en) * 2001-02-01 2002-08-08 Mochida Pharmaceutical Co., Ltd. Adiponectin-associated protein
JP4817514B2 (ja) 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
KR20030081520A (ko) * 2001-03-14 2003-10-17 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ１ 안타고니스트를 유효 성분으로서 함유하는 울병의치료제
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
AU2002306868A1 (en) 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
PL209822B1 (pl) 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
JP4230681B2 (ja) 2001-07-06 2009-02-25 株式会社東芝 高耐圧半導体装置
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP4269052B2 (ja) * 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
JP2003095977A (ja) * 2001-09-21 2003-04-03 Masafumi Yano 筋肉収縮・弛緩機能障害関連疾患の治療又は予防剤
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
JPWO2003043655A1 (ja) 2001-11-19 2005-03-10 小野薬品工業株式会社 頻尿の治療剤
EP1452530A4 (en) * 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
US20040171613A1 (en) 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (en) 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
JP2005521653A (ja) * 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
EP1489077A4 (en) 2002-02-01 2006-06-21 Dainippon Sumitomo Pharma Co 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
AU2003211997B2 (en) 2002-02-14 2009-01-29 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
WO2003091280A1 (en) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
CN1655696A (zh) * 2002-04-26 2005-08-17 日本烟草产业株式会社 棒状物品成形装置
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
JP2004103256A (ja) 2002-09-04 2004-04-02 Nippon Chemicon Corp 非常灯
EP1550660A1 (en) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
KR20050062551A (ko) 2002-09-20 2005-06-23 기린 비루 가부시키가이샤 α-글리코실세라미드를 유효 성분으로 하는 Ｃ형 간염 바이러스 억제제
US20060185025A1 (en) 2002-10-04 2006-08-17 Kirin Beer Kabushiki Kaisha Human artificial chromosome (hac) vector
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004042389A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
NZ539952A (en) 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
EP1439221B1 (en) 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag PDE core construct
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
TWI220798B (en) 2003-03-07 2004-09-01 Hitachi Cable Light-emitting diode array
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CA2519432C (en) 2003-03-17 2009-06-09 Japan Tobacco Inc. Pharmaceutical compositions comprising cetp inhibitors and a water-insoluble concentration-enhancing additive for the treatment of cardiovascular disease
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
WO2004085382A1 (ja) 2003-03-27 2004-10-07 Kirin Beer Kabushiki Kaisha 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
TW200500362A (en) 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
WO2004093816A2 (en) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
WO2004093813A2 (en) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20050009733A1 (en) * 2003-04-22 2005-01-13 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
US20040229803A1 (en) 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
WO2005013907A2 (en) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
US20050187221A1 (en) 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
CA2548309A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
US7165879B2 (en) 2004-03-25 2007-01-23 Red Devil Equipment Company Clamp lock apparatus and method for a paint mixer
EP1749102A4 (en) * 2004-04-22 2009-02-25 Kirin Pharma Kk TRANSGENIC ANIMALS AND USES THEREOF
CA2565024A1 (en) 2004-04-28 2005-11-10 Aetas Pharma Co., Ltd. Therapeutic agent for left ventricular diastolic dysfunction
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) * 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
AU2005260821B2 (en) * 2004-07-15 2010-02-18 Japan Tobacco Inc. Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
JP2006094849A (ja) 2004-08-30 2006-04-13 Kirin Brewery Co Ltd 相同組換え効率が向上した分化多能性細胞及びその利用
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7396829B2 (en) 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CA2599544A1 (en) 2005-02-28 2006-09-08 Japan Tobacco Inc. Novel aminopyridine compound with syk inhibitory activity
WO2006098394A1 (ja) 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
RS52601B (sr) 2013-04-30
DK2163248T3 (da) 2012-12-17
UA96914C2 (ru) 2011-12-26
HK1143581A1 (en) 2011-01-07
ES2394104T3 (es) 2013-01-21
EP2163248A1 (en) 2010-03-17
EP2127654B1 (en) 2013-05-22
NO20064843L (no) 2006-12-21
CA2560866A1 (en) 2005-10-13
HRP20120938T1 (hr) 2012-12-31
WO2005094457A2 (en) 2005-10-13
IL178157A (en) 2013-03-24
MA28629B1 (fr) 2007-06-01
JP2012250999A (ja) 2012-12-20
IL178157A0 (en) 2006-12-31
KR20120127739A (ko) 2012-11-23
PL2163248T3 (pl) 2013-01-31
EP2163248B1 (en) 2012-08-29
EA015010B1 (ru) 2011-04-29
KR20070041432A (ko) 2007-04-18
US7718644B2 (en) 2010-05-18
US20050215540A1 (en) 2005-09-29
AU2005227907A1 (en) 2005-10-13
WO2005094457A3 (en) 2006-04-27
AU2005227907B2 (en) 2010-12-16
EP2127654A1 (en) 2009-12-02
CN1980677A (zh) 2007-06-13
HK1137922A1 (en) 2010-08-13
CN1980677B (zh) 2011-12-21
GEP20115301B (en) 2011-10-10
CY1113426T1 (el) 2016-06-22
JP2007530561A (ja) 2007-11-01
NZ550750A (en) 2010-11-26
CN101704799A (zh) 2010-05-12
SG153862A1 (en) 2009-07-29
SI2163248T1 (sl) 2013-01-31
EP1734969A4 (en) 2009-04-29
CN101704799B (zh) 2013-06-05
EP1734969A2 (en) 2006-12-27
EA200601765A1 (ru) 2007-10-26
PT2163248E (pt) 2012-12-17
BRPI0509199A (pt) 2007-08-28
WO2005094457B1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
JP5274831B2 (ja) リアノジンレセプタ（ＲｙＲ２）の漏れを標的とする、新規な抗−不整脈性及び心不全用薬剤及びその使用
US20100152440A1 (en) NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)
US20040229781A1 (en) Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
HK1137922B (en) Benzothiazepine derivatives as ryanodine receptor (ryr2) inhibitors and their use in the treatment of cardiac diseases
HK1143581B (en) Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor and uses thereof
MXPA06010857A (en) Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof
MXPA06003878A (en) Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130515

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees